BRIEF published on 03/17/2025 at 07:05, 1 year ago Biophytis Publishes Promising Sarcopenia Trial Results Biophytis Clinical Trial Sarcopenia BIO101 Phase 2 Results
BRIEF published on 03/17/2025 at 07:05, 1 year ago Biophytis avance dans le traitement de la sarcopénie Biophytis Essais Cliniques Sarcopénie BIO101 Phase III
REGULATED PRESS RELEASE published on 03/17/2025 at 07:00, 1 year ago Biophytis revolutionizes sarcopenia Biophytis announces groundbreaking results from SARA-INT Phase II trial for BIO101 in sarcopenia, confirming Phase 3 readiness. Publication in JCSM highlights efficacy and safety Biophytis Clinical Trial Sarcopenia Phase II SARA-INT
REGULATED PRESS RELEASE published on 03/17/2025 at 07:00, 1 year ago Biophytis révolutionne la sarcopénie Biophytis révolutionne la sarcopénie avec BIO101. Résultats prometteurs de l'étude SARA-INT publiés. Passage à la Phase 3 confirmé. Importante avancée dans le traitement de la sarcopénie Biophytis Traitement Étude Clinique Sarcopénie BIO101
BRIEF published on 03/06/2025 at 07:05, 1 year ago Biophytis to Attend BIO-Europe Spring 2025 in Milan Biophytis Biotechnology Drug Development BIO-Europe 2025 Aging Diseases
BRIEF published on 03/06/2025 at 07:05, 1 year ago Biophytis participe à BIO-Europe Spring à Milan Biophytis Conference BIO-Europe Spring Innovation Biotechnologique Traitement Maladies Liées À L'âge
REGULATED PRESS RELEASE published on 03/06/2025 at 07:00, 1 year ago Biophytis annonce sa participation à la conférence BIO-Europe Spring à Milan Biophytis annonce sa participation à la conférence BIO-Europe Spring à Milan pour discuter de son principal candidat médicament, BIO101, dans l'obésité et la sarcopénie Biophytis Conference BIO-Europe Spring Sarcopénie Obésité
REGULATED PRESS RELEASE published on 03/06/2025 at 07:00, 1 year ago Biophytis announces its participation to the BIO-Europe Spring 2025 in Milan Biophytis announces participation in BIO-Europe Spring 2025 in Milan. Chief Business Officer to attend meetings. Focus on lead drug candidate BIO101 in obesity and sarcopenia Biophytis Sarcopenia BIO101 Obesity BIO-Europe Spring 2025
BRIEF published on 02/25/2025 at 07:05, 1 year ago Biophytis au 15ème Congrès International sur la Fragilité et la Sarcopénie Biophytis Sarcopénie Traitements Innovants Fragilité Congrès ICFSR
BRIEF published on 02/25/2025 at 07:05, 1 year ago Biophytis to Present at 15th International Conference on Frailty and Sarcopenia Research Biophytis Sarcopenia BIO101 ICFSR 2025 Obesity Research
Published on 03/24/2026 at 12:35, 1 hour 2 minutes ago Silver X Acquires the High-Grade Pampas Gold-Silver Project, Expanding its Precious Metal Asset Base in Peru
Published on 03/24/2026 at 12:33, 1 hour 4 minutes ago Mako Mining Completes Acquisition of Mt. Hamilton in Nevada
Published on 03/24/2026 at 12:30, 1 hour 7 minutes ago Orogen Reports Record 2025 Financial Performance and Positions for Continued Growth in 2026
Published on 03/24/2026 at 12:30, 1 hour 7 minutes ago Sidney Resources Corporation Identifies District-Scale Structural and Hydrothermal System at Warren Project; Survey Confirms Strategic Claim Position Within Core Target Corridor
Published on 03/24/2026 at 12:30, 1 hour 7 minutes ago Avidian Gold Announces Non-Brokered Private Placement for Gross Proceeds of up to $750,000
Published on 03/24/2026 at 13:23, 13 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 03/24/2026 at 13:05, 31 minutes ago Fortegra Selects Duck Creek Reinsurance and Clarity to Support Strategic Growth
Published on 03/24/2026 at 13:05, 31 minutes ago Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
Published on 03/24/2026 at 12:53, 43 minutes ago Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): Kaufen
Published on 03/24/2026 at 12:37, 59 minutes ago CENIT concludes fiscal year 2025 with a strong operational Q4 and looks confidently toward the current year (EBITDA Forecast 2026 +46.6%)
Published on 03/24/2026 at 10:58, 2 hours 39 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of February 28, 2026
Published on 03/24/2026 at 10:58, 2 hours 39 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 28 février 2026
Published on 03/24/2026 at 07:45, 5 hours 52 minutes ago François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 5 hours 52 minutes ago La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 6 hours 7 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
